<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569437</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-0462</org_study_id>
    <nct_id>NCT02569437</nct_id>
  </id_info>
  <brief_title>Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps</brief_title>
  <official_title>The Role of Doxycycline in Management of Moderate to Severe Chronic Rhinosinusitis With Nasal Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Department of Otolaryngology at Mount Sinai is looking for adults with sinus disease with
      polyps, otherwise called chronic rhinosinusitis with nasal polyps (CRSwNP). Patients may be
      eligible to enroll in a study offering a cutting-edge therapy to help reduce symptoms and
      avoid surgery. The treatment combines an antibiotic (doxycycline) with oral steroids. Oral
      steroids are the mainstay of medical management for patients with CRSwNP. However, recent
      studies have shown that doxycycline helps improve symptoms as well by reducing inflammation
      and killing common bacteria that can cause symptoms. This study is the first to evaluate this
      combination regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An eligible patient may be treated with either doxycycline and oral steroids OR placebo
      (sugar pill) and oral steroids for three weeks. Volunteers will participate in the study for
      to 12 weeks, and will have 4 research visits of 1 hour duration. At each study visit, the
      patient will under go an endoscopic evaluation and asked to complete a questionnaire
      describing symptoms. There is no additional cost to be enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A high percentage of patients were dropping out of the study and were not able to complete the
    protocol.
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sino-nasal Outcome Test (SNOT 22)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>a validated 22 item quality of life questionnaire for patients with chronic rhinosinusitis. Range of 0 to 110, higher scores indicate worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Nasal Polyp Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>0- Absence of nasal polyps
Polyps confined to the middle meatus and not beyond the inferior border of the middle turbinate
Polyps reaching below the lower border of the middle turbinate
Large polyps extending to the lower border of the inferior turbinate or medial to the middle turbinate
Large polyps extending to the lower border of the inferior turbinate or medial to the middle turbinate Nasal polyp scores. The score is determined for each nostril, and the two scores added for a total nasal polyp score. Range of 0 to 8, graded on a size system from 0 to 4 and summed from the right and left nostrils.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Middle Meatus Culture</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Culture swab for the presence or absence of microbial growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Symptom Composite Scoring</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>A subjective symptom score will be extracted from the patient's score (on a scale of 0-5, where 0 defines no problems with the given symptom and 5 defines maximal problems ) on the SNOT-22 for each fo the following symptoms: &quot;blockage/congestion,&quot; &quot;runny nose,&quot; &quot;post-nasal discharge,&quot; &quot;facial pain/pressure,&quot; and &quot;sense of taste/smell.&quot; Range of 0 to 25, with higher score reflecting worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The visual analog scale for overall symptoms will be used to define disease severity. Range of 0 to 10. As per the European Position Paper 2012, mild, moderate, and severe disease will be defined as 0 to and including 3, &gt; 3 to and including 7, and &gt; 7 to and including 10, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Polyp of Nasal Sinus</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nasal saline spray</intervention_name>
    <description>nasal saline sprays: 2 sprays each nostril three times a day</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flonase</intervention_name>
    <description>daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>nasal steroid spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>placebo pill to match doxycycline</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nasal polyps on nasal endoscopy.

          -  The patient has moderate to severe disease, defined by moderate to severe subjective
             symptoms (a score greater than 3 on a 10-cm VAS).

          -  The patient is at least 18 years old.

          -  The patient is able to understand and give informed consent.

          -  The patient has clinically diagnosed chronic rhinosinusitis with nasal polyps
             according to the AAO-HNS diagnostic criteria: At least 2 of the following
             symptoms/signs:

               -  Mucopurulent drainage (anterior, posterior, or both)

               -  Nasal obstruction (congestion)

               -  Facial pain-pressure-fullness

               -  Decreased sense of smell

               -  and symptoms lasting 12 weeks or longer.

        Exclusion Criteria:

          -  The patient has a history of treatment with oral corticosteroids in the past 4 weeks.
             ,

          -  The patient has cystic fibrosis.

          -  The patient has primary ciliary dyskinesia.

          -  The patient has diabetes.

          -  The patient has had sinus surgery in the past 3 months.

          -  The patient has an allergy to doxycycline or related tetracyclines or glucocorticoids.

          -  The patient is a minor.

          -  The patient is a prisoner.

          -  The patient has a psychiatric illness or developmental delay, which would interfere
             with understanding of the study and provision of informed consent.

          -  The patient is a breastfeeding mother. The effects of the drugs used in this study
             (doxycycline) on breast milk are unknown and thus, these patients will be excluded
             from the study

          -  The patient has a history of HIV or other known cause of immunosuppression, or is
             actively taking immunosuppressive medications due to organ transplantation, rheumatoid
             disease, or other medical conditions.

          -  The patient is on penicillin; antacids containing aluminum, calcium, magnesium, or
             iron; bismuth subsalicylate; barbiturates; carbamazepine; and phenytoin; as well as
             tetracycline and Penthane.

          -  Pregnancy. Doxycycline, a tetracycline, is a known teratogen. For this reason women of
             child-bearing potential are suggested to take a form of contraception for the duration
             that they are taking doxycycline., Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

        Pregnancy Testing. Women of childbearing potential are required to have a negative serum
        pregnancy test (with a sensitivity of at least 25 mIU/mL) prior to the first dose of drug.
        No further pregnancy tests are required since after this visit the patient will no longer
        be taking tetracycline after 3 weeks.

        Women of childbearing potential are defined as follows:

          -  Patients with regular menses

          -  Patients with amenorrhea, irregular cycles, or using a contraceptive method that
             precludes withdrawal bleeding

          -  Women who have had a tubal ligation

        Women are considered not to be of childbearing potential for the following reasons:

          -  The patient has undergone hysterectomy and/or bilateral oophorectomy.

          -  The patient is post-menopausal defined by amenorrhea for at least 1 year in a woman &gt;
             45 years old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin D Malkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahns School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satish Govindaraj, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2015</study_first_posted>
  <results_first_submitted>October 31, 2017</results_first_submitted>
  <results_first_submitted_qc>December 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2018</results_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Benjamin D Malkin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>doxycycline</keyword>
  <keyword>oral methylprednisone</keyword>
  <keyword>sinusitis with nasal polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from September 2014 to April 2016 at the Mount Sinai Department of Otolaryngology—Head &amp; Neck Surgery rhinology practice.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Doxycycline</title>
          <description>Doxycycline plus oral methylprednisolone and nasal saline sprays
Doxycycline: Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
methylprednisolone: oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
nasal saline spray: nasal saline sprays: 2 sprays each nostril three times a day
Flonase: daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
methylprednisolone: oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
Flonase: daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
sugar pill: placebo pill to match doxycycline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Doxycycline</title>
          <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.5" spread="13.8"/>
                    <measurement group_id="B2" value="44.1" spread="12.2"/>
                    <measurement group_id="B3" value="47.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with Prior Endoscopic Sinus Surgery (ESS)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sino-nasal Outcome Test (SNOT 22)</title>
        <description>a validated 22 item quality of life questionnaire for patients with chronic rhinosinusitis. Range of 0 to 110, higher scores indicate worse outcome</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>An additional 7 patients in the treatment group and 10 patients in the placebo group completed SNOT-22 scores via phone calls, even after study withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
          </group>
        </group_list>
        <measure>
          <title>Sino-nasal Outcome Test (SNOT 22)</title>
          <description>a validated 22 item quality of life questionnaire for patients with chronic rhinosinusitis. Range of 0 to 110, higher scores indicate worse outcome</description>
          <population>An additional 7 patients in the treatment group and 10 patients in the placebo group completed SNOT-22 scores via phone calls, even after study withdrawal.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" spread="24.3"/>
                    <measurement group_id="O2" value="54.4" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7" spread="6.2"/>
                    <measurement group_id="O2" value="49.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Nasal Polyp Score</title>
        <description>0- Absence of nasal polyps
Polyps confined to the middle meatus and not beyond the inferior border of the middle turbinate
Polyps reaching below the lower border of the middle turbinate
Large polyps extending to the lower border of the inferior turbinate or medial to the middle turbinate
Large polyps extending to the lower border of the inferior turbinate or medial to the middle turbinate Nasal polyp scores. The score is determined for each nostril, and the two scores added for a total nasal polyp score. Range of 0 to 8, graded on a size system from 0 to 4 and summed from the right and left nostrils.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>There were 12 subject withdrawals in the treatment group and 14 in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Nasal Polyp Score</title>
          <description>0- Absence of nasal polyps
Polyps confined to the middle meatus and not beyond the inferior border of the middle turbinate
Polyps reaching below the lower border of the middle turbinate
Large polyps extending to the lower border of the inferior turbinate or medial to the middle turbinate
Large polyps extending to the lower border of the inferior turbinate or medial to the middle turbinate Nasal polyp scores. The score is determined for each nostril, and the two scores added for a total nasal polyp score. Range of 0 to 8, graded on a size system from 0 to 4 and summed from the right and left nostrils.</description>
          <population>There were 12 subject withdrawals in the treatment group and 14 in the placebo group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.8"/>
                    <measurement group_id="O2" value="6.5" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.5"/>
                    <measurement group_id="O2" value="4.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Middle Meatus Culture</title>
        <description>Culture swab for the presence or absence of microbial growth</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
          </group>
        </group_list>
        <measure>
          <title>Middle Meatus Culture</title>
          <description>Culture swab for the presence or absence of microbial growth</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Culture growth at initial visit and 12 week visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Culture growth initial visit, none at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No growth initial visit, but growth at 12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Symptom Composite Scoring</title>
        <description>A subjective symptom score will be extracted from the patient’s score (on a scale of 0-5, where 0 defines no problems with the given symptom and 5 defines maximal problems ) on the SNOT-22 for each fo the following symptoms: “blockage/congestion,” “runny nose,” “post-nasal discharge,” “facial pain/pressure,” and “sense of taste/smell.” Range of 0 to 25, with higher score reflecting worse symptoms.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>There were 12 subject withdrawals in the treatment group and 14 in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Symptom Composite Scoring</title>
          <description>A subjective symptom score will be extracted from the patient’s score (on a scale of 0-5, where 0 defines no problems with the given symptom and 5 defines maximal problems ) on the SNOT-22 for each fo the following symptoms: “blockage/congestion,” “runny nose,” “post-nasal discharge,” “facial pain/pressure,” and “sense of taste/smell.” Range of 0 to 25, with higher score reflecting worse symptoms.</description>
          <population>There were 12 subject withdrawals in the treatment group and 14 in the placebo group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="5.2"/>
                    <measurement group_id="O2" value="17.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="1.5"/>
                    <measurement group_id="O2" value="13.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale</title>
        <description>The visual analog scale for overall symptoms will be used to define disease severity. Range of 0 to 10. As per the European Position Paper 2012, mild, moderate, and severe disease will be defined as 0 to and including 3, &gt; 3 to and including 7, and &gt; 7 to and including 10, respectively.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>There were 12 subject withdrawals in the treatment group and 14 in the placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Doxycycline</title>
            <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale</title>
          <description>The visual analog scale for overall symptoms will be used to define disease severity. Range of 0 to 10. As per the European Position Paper 2012, mild, moderate, and severe disease will be defined as 0 to and including 3, &gt; 3 to and including 7, and &gt; 7 to and including 10, respectively.</description>
          <population>There were 12 subject withdrawals in the treatment group and 14 in the placebo group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.5"/>
                    <measurement group_id="O2" value="8.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.7"/>
                    <measurement group_id="O2" value="4.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Doxycycline</title>
          <description>Doxycycline plus oral methylprednisolone and nasal saline sprays</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Power not adequate and study is at risk for a Type II error - study was ended prior to complete sample size accrual. Study recruited high percentage of severe disease patients, thus did not accurately represent moderate disease patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Benjamin Malkin</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <email>Benjamin.D.Malkin@kp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

